The current financial score of aTyr Pharma Inc is 6.90. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 29.07%.
The current valuation score of aTyr Pharma Inc is 9.25. Its current P/E ratio is -8.30, which is -97.97% below the recent high of -0.17 and -24.16% above the recent low of -10.31.
The current earnings forecast score of aTyr Pharma Inc is 7.11. The average price target is 113.33, with a high of 280.00 and a low of 40.00.
The current price momentum score of aTyr Pharma Inc is 6.42. Currently, the stock price is trading between the resistance level at 8.03 and the support level at 4.13, making it suitable for range-bound swing trading.
The current institutional shareholding score of aTyr Pharma Inc is 5.00. The latest institutional shareholding proportion is 56.72%, representing a quarter-over-quarter decrease of 24.02%.
The current risk assessment score of aTyr Pharma Inc is 1.30. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.